Retinol 中文名称: 维生素a

别名: Prepalin; Testavol; Vitamin A; alcohol All-trans-retinol; all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; Axerophthol; Vafol; Avibon; Afaxin; Retinol; Aoral; Biosterol; Vitamin A Chocola A; Alphasterol; 维生素a;视黄醇;维生素甲;3,7-二甲基-9-(2,6,6-三甲基-1-环己烯-1-基)-2,4,6,8-壬四烯-1-醇;全反式-视黄醇;视黄素;维生素A1;维生素A醇;3,7-二甲基-9-(2,6,6-三甲基-1-环已稀);维生素A(视黄醇);Vitamin A 维生素A(视黄醇); 反式视黄醇标准品; 全反式视黄醇;视黄醇(维生素A) 标准品;维生素 A（VITAMIN A）;维生素A（醇溶）;维生素A（醋酸盐）;维生素A,BR;维生素A,视黄醇; 全反式-视黄醇,维生素甲, 3,7-二甲基-9-(2,6,6-三甲基-1-环己烯-1-基)-2,4,6,8-壬四烯-1-醇,维生素A醇,视黄素,维生素A1;视黄醇标准品;维生素A,50;全反式-3,7-二甲基-9-(2,6,6-三甲基-1-环己烯-1-基)-2,4,6,8-壬四烯-1-醇;抗干眼醇;维生素 A 醇溶液;视黄醇溶液;维生素 A 醇;维生素 A;维生素 A1

目录号: V8022 纯度: ≥98%

COA 产品数据产品说明书 SDS

视黄醇（也称为维生素 A1）是维生素 A 家族的一种脂溶性维生素，是一种天然存在的化合物，可以在食物中找到，经常用作膳食补充剂来治疗和预防维生素 A 缺乏症，尤其是维生素 A 缺乏症。结果导致干眼症。

Retinol CAS号: 68-26-8
产品类别: Vitamin

产品仅用于科学研究，不针对患者销售

规格	价格	库存	数量
1mg
5mg
10mg
25mg
50mg
100mg
250mg
500mg
1g
Other Sizes

加入购物车结帐大包装询价

020-31522723 sales@invivochem.cn

点击了解更多

与全球5000+客户建立关系
覆盖全球主要大学、医院、科研院所、生物/制药公司等
产品被大量CNS顶刊文章引用

InvivoChem产品被CNS等顶刊论文引用

Nature 2025, 643(8070):192-200.

Nature 2024 Dec 18.

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nat Neurosci 2024, 27:1468-1474.

Science Adv 2025, 11(33):eadr5199.

Nat Metab 2024, 6: 1108-1127.

Cell Stem Cell 2024, 31:106-126.e13.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2023,56(3):620-634.e11.

Immunity 2024,57:2651-2668.e12.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

纯度/质量控制文件

批次：

纯度: ≥98%

COA

MSDS

产品说明书

产品描述
生物活性&实验参考方法
化学信息
溶解度数据
计算器
临床试验信息

产品描述

视黄醇（也称为维生素 A1）是维生素 A 家族的一种脂溶性维生素，是一种天然存在的化合物，可以在食物中找到，经常用作膳食补充剂来治疗和预防维生素 A 缺乏症，特别是导致干眼症的原因。它是一种有效的抗氧化剂，具有脂过氧自由基清除活性和荧光特性。维生素 A 可代谢为视黄酸，视黄酸是视黄酸受体 (RAR) 和类视黄醇 X 受体 (RXR) 的配体。在发育、生殖、免疫、器官发生和癌症中的作用。

生物活性&实验参考方法

靶点	Retinoid receptors (RARs)
体外研究 (In Vitro)	视黄醇是脂溶性维生素视黄醇。维生素A结合并激活类视黄醇受体（RARs），从而诱导某些癌症细胞类型的细胞分化和凋亡，并抑制致癌作用。维生素A在许多生理过程中起着至关重要的作用，包括视网膜的正常功能、靶组织的生长和分化、生殖器官的正常功能以及免疫功能的调节在这项研究中，尚不清楚哪种分子是诱导RAW264细胞中GSH产生增强的确切分子。然而，一种可能性是β-胡萝卜素被代谢成视黄醇，然后视黄醇实际上对GSH合成产生了增强作用。众所周知，β-胡萝卜素是维生素A的前体，由β-胡萝卜素转化而来的视黄醇（维生素A）具有潜在的生理功能，其中最具代表性的是视觉。据报道，在之前的研究中，用添加了β-胡萝卜素的培养基孵育后，RAW264细胞中未检测到视黄醇（Katsuura等人，2009）。同样，也有报道称，在RAW264细胞中未检测到β-胡萝卜素-15,15′-单加氧酶（BCMO1）的mRNA，该酶催化β-胡萝卜素或β-隐黄质产生类维生素A。与此相反，Zolberg等人报告称，在与9-顺式β-胡萝卜素孵育后，RAW264.7细胞中检测到BCMO1蛋白及其产物视黄醇（Zolberg-Relevy等人，2015）。另一种可能性是，β-胡萝卜素和视黄醇可能至少在一定程度上对RAW264细胞中GSH合成的增强具有几乎相同的作用[1]。
体内研究 (In Vivo)	IMQ治疗的小鼠出现红斑、鳞屑和皮肤增厚。与对照组相比，IMQ治疗组有以下变化：1）血清和皮损皮肤中的白细胞介素（IL）-17A、IL-23和肿瘤坏死因子（TNF）-α水平显著升高（均p<0.001）；2）皮损皮肤视黄醇水平略有升高（p=0.364），但血清视黄醇含量无明显变化；3） STRA6在皮损皮肤（p=0.021）和血清（p=0.034）中均上调；4）血清中RBP4水平升高（p=0.042），但在病变皮肤中仅呈上升趋势（p=0.273）；5）介导视黄酸形成和转化的蛋白质和酶在病变皮肤中上调。[2] 结论：随着银屑病小鼠对维生素A需求的增加，视黄醇从循环系统转移到靶组织。RBP4、STRA6和从视黄醇到视黄酸的转化上调，这可能是银屑病皮肤病变形成机制的一部分。我们提出，形成了一种维持银屑病严重程度的正反馈机制[2]。
细胞实验	在这项研究中，研究人员评估了视黄醇和视黄酸（RA）增强小鼠培养的巨噬细胞系RAW264细胞内谷胱甘肽（GSH）水平的潜力，以研究RA信号通路是否参与β-胡萝卜素诱导的GSH增强。 [1] 方法和结果：我们检测了在添加了β-胡萝卜素和各种抑制剂（RA受体（RAR）α的ER50891、RARβ/γ的CD2665或所有亚型维甲酸X受体（RXR）的HX531）的培养基中培养的RAW264细胞中的GSH水平，以验证每种抑制剂对β-胡萝卜素的活性，以及在添加了各种刺激物（RARα的AM80、RARα中的CD2314、RARγ的CD437或RXR的SR11237）的培养基中培养的细胞中的谷胱甘肽水平，以将其活性与β-胡萝卜素有比较。我们还检测了在全反式RA或视黄醇补充培养基中培养的RAW264细胞中的GSH水平和谷氨酸半胱氨酸连接酶（GCL）表达。任何测试的拮抗剂都没有抑制GSH的产生，除了β-胡萝卜素外，没有激动剂诱导GSH的生产。视黄醇（但不是全反式RA）增强了GSH的合成，增加了GCL的表达，与β-胡萝卜素相似。 [1] 结论：RA信号通路可能不参与β-胡萝卜素诱导的RAW264细胞GSH水平的升高，而视黄醇与β-胡萝卜素一样，可以提高GSH水平和GCL表达。
动物实验	30只小鼠被分为4个研究组：两组分别接受IMQ治疗3天或6天（分别为A组和B组），两组分别接受凡士林治疗3天或6天（分别为C组和D组）。采用酶联免疫吸附试验、苏木精-伊红染色、免疫化学、实时逆转录聚合酶链式反应和RNA测序等方法分析小鼠病变部位和非病变部位的血液和皮肤样本。[2]
药代性质 (ADME/PK)	吸收、分布和排泄易于被正常胃肠道吸收。维生素A会分布到母乳中……。正常情况下，血液中循环的维生素A与脂蛋白结合的比例不到5%，但当摄入过量导致肝脏储存饱和时，这一比例可高达65%。高脂蛋白血症时，与脂蛋白结合的维生素A量可能会增加。维生素A从肝脏释放后，会与视黄醇结合蛋白（RBP）结合。大部分维生素A以与RBP结合的视黄醇形式循环。储存：主要储存在肝脏（大约相当于成人2年的需求量），少量储存在肾脏和肺组织中。锌是肝脏动员维生素A储备所必需的。超过90%的预成型维生素A摄入量以视黄醇酯的形式存在，通常为棕榈酸视黄酯。……当摄入过量时，部分维生素会随粪便排出。……吸收……与脂质吸收相关，并受胆汁促进。……水性分散体……比油性溶液吸收更快。有关维生素A（共9种）的更多吸收、分布和排泄（完整）数据，请访问HSDB记录页面。代谢/代谢物肝脏代谢。视黄醇与葡萄糖醛酸结合；β-葡萄糖醛酸苷经肠肝循环氧化为视黄醇和视黄酸。视黄酸发生脱羧反应并与葡萄糖醛酸结合。视黄醇在上皮组织中转化为视黄醇磷酸酯，该中间体在微粒体酶的催化下，以鸟苷二磷酸甘露糖为糖基供体，进一步代谢为甘露糖基视黄醇磷酸酯。维生素A介导甘露糖向特定糖蛋白的转移。视黄醇部分结合形成β-葡萄糖醛酸苷，后者经肠肝循环并氧化为视黄醛和视黄酸。在视网膜内，全反式视黄醇经醇脱氢酶氧化为视黄醛，然后异构化为11-顺式异构体。11-顺式异构体与视杆细胞中的视蛋白结合生成视紫红质，并与视锥细胞中的不同视蛋白结合生成三种不同的碘紫红质色素。视黄酸（RA）是维生素A（视黄醇）的生物活性代谢产物，它作用于细胞，建立或改变基因活性模式。视黄醇在两种酶的作用下转化为视黄酸：视黄醇脱氢酶和视黄醛脱氢酶。在细胞核内，视黄酸 (RA) 作为配体激活两类转录因子：视黄酸受体 (RAR) 和类视黄醇 X 受体 (RXR)。RAR 和 RXR 形成异二聚体并与 RA 反应基因的上游序列结合。视黄醇在人体内的已知代谢产物包括视黄醛和 4-羟基视黄醇。在肝脏中，视黄醇与葡萄糖醛酸结合；β-葡萄糖醛酸苷经肠肝循环氧化为视黄醇和视黄酸。视黄酸脱羧并与葡萄糖醛酸结合。半衰期：1.9 小时生物半衰期 1.9 小时动物肝脏中维生素 A 的储备以约 50 天的半衰期减少……
毒性/毒理 (Toxicokinetics/TK)	毒性概述视觉：维生素A（全反式视黄醇）在视网膜中转化为视黄醛的11-顺式异构体，即11-顺式视黄醛。11-顺式视黄醛在视网膜中发挥作用，将光信号转化为视觉所需的神经信号。11-顺式视黄醛与视紫红质中的视蛋白结合，在光照下异构化为全反式视黄醛。这一过程触发神经冲动传递至大脑，从而实现对光的感知。随后，全反式视黄醛从视蛋白中释放出来，并被还原为全反式视黄醇。全反式视黄醇在黑暗中异构化为11-顺式视黄醇，然后氧化为11-顺式视黄醛。11-顺式视黄醛与视蛋白重组形成视紫红质。夜盲症或弱光视力障碍是由于11-顺式视黄醛无法快速重新合成所致。上皮分化：维生素A在上皮分化以及其他生理过程中发挥作用，这涉及维生素A与两类核类视黄醇受体（视黄酸受体，RAR；以及类视黄醇X受体，RXR）的结合。这些受体作为配体激活的转录因子，调节基因转录。当维生素A不足以与这些受体结合时，细胞的自然分化和生长就会受到干扰。相互作用胰岛素拮抗维生素A的致畸作用。抗甲状腺化合物甲基硫脲嘧啶增强维生素A的致畸作用。甲状腺素拮抗维生素A的致畸作用。在大鼠中，通过给母鼠适当注射可的松，显著增加了因维生素A过量引起的头部先天性畸形的发生率。有关维生素A的更多相互作用（完整）数据（共19项），请访问HSDB记录页面。非人类毒性值小鼠腹腔注射LD50：1510 mg/kg（10天）小鼠口服LD50：2570 mg/kg（10天）鸡口服LD50 3.15 - 3.7 克/公斤体重
参考文献	[1]. Retinol but not retinoic acid can enhance the glutathione level, in a manner similar to β-carotene, in a murine cultured macrophage cell line. Food Sci Nutr . 2018 Jul 20;6(6):1650-1656. [2]. Retinol and vitamin A metabolites accumulate through RBP4 and STRA6 changes in a psoriasis murine model. Nutr Metab (Lond) . 2020 Jan 13:17:5.
其他信息	治疗用途维生素A仅用于预防或治疗维生素A缺乏症。维生素A缺乏症可能由营养不良或肠道吸收不良引起，但健康个体在摄入充足均衡饮食的情况下不会出现维生素A缺乏症。为预防维生素A缺乏症，建议改善饮食，而非补充维生素A。为治疗维生素A缺乏症，建议补充维生素A。/美国产品标签包含/ 对于食用未强化配方奶粉的婴儿或患有以下情况的个体（基于已确诊的维生素A缺乏症），建议增加维生素A摄入量和/或补充维生素A：腹泻；胃切除术；甲状腺功能亢进；慢性感染；肠道疾病：乳糜泻、腹泻、局部性口炎性腹泻、局限性肠炎；与胰腺功能不全相关的吸收不良综合征：胰腺疾病、囊性纤维化；麻疹；严重蛋白质缺乏症、长期应激；干眼症。/已包含在美国产品标签中/ 一些特殊的饮食（例如，大幅限制食物选择，尤其是含脂肪食物的减脂饮食）可能无法提供每日最低推荐维生素A摄入量。接受全肠外营养（TPN）的患者、体重快速下降的患者或营养不良的患者，由于膳食摄入不足，需要补充维生素A。大多数维生素和矿物质的推荐摄入量在孕期会增加。许多医生建议孕妇服用多种维生素和矿物质补充剂，尤其是那些膳食摄入不足的孕妇以及高危人群（例如，怀有多胎的孕妇、重度吸烟者以及酗酒和吸毒者）。过量服用复合维生素和矿物质补充剂可能对母亲和/或胎儿有害，应避免。有关维生素 A（共 7 种）的更多治疗用途（完整）数据，请访问 HSDB 记录页面。药物警告妊娠风险类别：X / 妊娠期间禁用。动物或人体研究，或研究性报告或上市后报告，均已证实存在胎儿畸形或风险，且其危害明显大于对患者的任何潜在益处。/ /肠外维生素A/ 剂量不超过生理需求的维生素A通常无毒。尚无足够数据表明维生素A可以降低某些类型癌症的发生率。 ……维生素A尚未被证实对治疗肾结石、甲状腺功能亢进、贫血、神经系统退行性疾病、晒伤、肺部疾病、耳聋、骨关节炎、炎症性肠病或银屑病有效。有关维生素A（共9条）的更多药物警告（完整）数据，请访问HSDB记录页面。药效学维生素A可有效治疗维生素A缺乏症。维生素A是指一组脂溶性物质，其结构与全反式视黄醇或视黄醇（或称视黄醇）相关，并具有与其相同的生物活性。维生素A在视觉、上皮分化、生长、生殖、胚胎发生过程中的模式形成、骨骼发育、造血和大脑发育中发挥着至关重要的作用。它对维持免疫系统的正常功能也至关重要。

*注: 文献方法仅供参考, InvivoChem并未独立验证这些方法的准确性

化学信息 & 存储运输条件

分子式	C20H30O
分子量	286.45
精确质量	286.229
元素分析	C, 83.86; H, 10.56; O, 5.59
CAS号	68-26-8
PubChem CID	445354
外观&性状	Solvated crystals from polar solvents, such as methanol or ethyl formate
密度	1.0±0.1 g/cm3
沸点	421.2±14.0 °C at 760 mmHg
熔点	144 to 147 °F (NTP, 1992) ; 62-64 °C ; Pale yellow prismatic crystals from methanol; mp: 57-58 °C; UV max (ethanol): 326 nm (E=1,550, 1%, 1 cm) /Retinol acetate/ ; Amorphous or crystalline; mp: 28-29 °C; UV max (ethanol); 325-328 nm (E=975, 1%, 1 cm) /Retinol palmitate/ ; 61 - 63 °C
闪点	147.3±16.4 °C
蒸汽压	0.0±2.3 mmHg at 25°C
折射率	1.549
LogP	6.84
tPSA	20.23
氢键供体(HBD)数目	1
氢键受体(HBA)数目	1
可旋转键数目(RBC)	5
重原子数目	21
分子复杂度/Complexity	496
定义原子立体中心数目	0
SMILES	CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/CO)/C)/C
InChi Key	FPIPGXGPPPQFEQ-OVSJKPMPSA-N
InChi Code	InChI=1S/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+
化学名	(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
别名	Prepalin; Testavol; Vitamin A; alcohol All-trans-retinol; all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol; Axerophthol; Vafol; Avibon; Afaxin; Retinol; Aoral; Biosterol; Vitamin A Chocola A; Alphasterol;
HS Tariff Code	2934.99.9001
存储方式	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
运输条件	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

溶解度数据

溶解度 (体外实验)	May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
溶解度 (体内实验)	注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。注射用配方 (IP/IV/IM/SC等) 注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline) 生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。注射用配方 2:* DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline) 注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil) 示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。 View More 注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)] 20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。注射用配方 5:* 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline) 注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline) 注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) 注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil) 注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline) 口服配方口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠) 口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素) 示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。 View More 口服配方 3: 溶解于 PEG400 (聚乙二醇400) 口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素) 口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素) 口服配方 6: 做成粉末与食物混合注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。请根据您的实验动物和给药方式选择适当的溶解配方/方案： 1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL； 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果，工作液请现配现用！ 6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们; 7、以上所有助溶剂都可在 Invivochem.cn网站购买。

溶解度 (体外实验)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

溶解度 (体内实验)

注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。

注射用配方
(IP/IV/IM/SC等)

注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。

View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

口服配方

口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。

View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、以上所有助溶剂都可在 Invivochem.cn网站购买。

制备储备液		1 mg	5 mg	10 mg
	1 mM	3.4910 mL	17.4551 mL	34.9101 mL
	5 mM	0.6982 mL	3.4910 mL	6.9820 mL
	10 mM	0.3491 mL	1.7455 mL	3.4910 mL

1、根据实验需要选择合适的溶剂配制储备液 (母液)：对于大多数产品，InvivoChem推荐用DMSO配置母液 (比如：5、10、20mM或者10、20、50 mg/mL浓度），个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;

2、如果您找不到您想要的溶解度信息，或者很难将产品溶解在溶液中，请联系我们;

3、建议使用下列计算器进行相关计算（摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等）;

4、母液配好之后，将其分装到常规用量，并储存在-20°C或-80°C，尽量减少反复冻融循环。

计算器

质量

浓度

体积

分子量*

计算重置

摩尔浓度计算器可计算特定溶液所需的质量、体积/浓度，具体如下：

计算制备已知体积和浓度的溶液所需的化合物的质量
计算将已知质量的化合物溶解到所需浓度所需的溶液体积
计算特定体积中已知质量的化合物产生的溶液的浓度

参见示例

使用摩尔浓度计算器计算摩尔浓度的示例如下所示：
假如化合物的分子量为350.26 g/mol，在5mL DMSO中制备10mM储备液所需的化合物的质量是多少？

在分子量（MW）框中输入350.26
在“浓度”框中输入10，然后选择正确的单位（mM）
在“体积”框中输入5，然后选择正确的单位（mL）
单击“计算”按钮
答案17.513 mg出现在“质量”框中。以类似的方式，您可以计算体积和浓度。

浓度 (起始)

体积 (起始)

浓度 (终)

体积 (终)

计算重置

稀释计算器可计算如何稀释已知浓度的储备液。例如，可以输入C1、C2和V2来计算V1，具体如下：

制备25毫升25μM溶液需要多少体积的10 mM储备溶液？
使用方程式C1V1=C2V2，其中C1=10mM，C2=25μM，V2=25 ml，V1未知：

在C1框中输入10，然后选择正确的单位（mM）
在C2框中输入25，然后选择正确的单位（μM）
在V2框中输入25，然后选择正确的单位（mL）
单击“计算”按钮
答案62.5μL（0.1 ml）出现在V1框中

分子式

分子量

g/mol

计算重置

分子量计算器可计算化合物的分子量 (摩尔质量)和元素组成，具体如下：

注：化学分子式大小写敏感：C12H18N3O4 c12h18n3o4
计算化合物摩尔质量（分子量）的说明：

要计算化合物的分子量 (摩尔质量)，请输入化学/分子式，然后单击“计算”按钮。

分子质量、分子量、摩尔质量和摩尔量的定义：

分子质量（或分子量）是一种物质的一个分子的质量，用统一的原子质量单位（u）表示。（1u等于碳-12中一个原子质量的1/12）
摩尔质量（摩尔重量）是一摩尔物质的质量，以g/mol表示。

配液体积

质量

配液浓度

计算重置

配液计算器可计算将特定质量的产品配成特定浓度所需的溶剂体积 (配液体积)

输入试剂的质量、所需的配液浓度以及正确的单位
单击“计算”按钮
答案显示在体积框中

动物体内实验配方计算器（澄清溶液）

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量 mg/kg

动物平均体重 g

每只动物给药体积 μL

动物数量

第二步：请输入动物体内配方组成（配方适用于不溶/难溶于水的化合物），不同的产品和批次配方组成不同，如对配方有疑问，可先联系我们提供正确的体内实验配方。此外，请注意这只是一个配方计算器，而不是特定产品的确切配方。

% DMSO

% Tween 80

% ddH₂O

计算重置

计算结果:

工作液浓度： mg/mL；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度，请首先与我们联系。

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意： (1) 请确保溶液澄清之后，再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶；
(2) 一定要按顺序加入溶剂 (助溶剂) 。

临床试验信息

Title:Effect of Vitamin A Supplementation on Idiopathic Scoliosis
Status:Recruiting
updateDate:2026-05-15
Ctid:NCT07335991

Link: https://clinicaltrials.gov/ct2/show/NCT07335991

Conditions:Vitamin A Deficiency|Idiopathic Scoliosis
Interventions:Vitamin A
Phase:N/A

Title:Oral Vitamin A Supplementation for Prevention of Bronchopulmonary Dysplasia in Preterm Infants
Status:Completed
updateDate:2026-05-11
Ctid:NCT07577180

Link: https://clinicaltrials.gov/ct2/show/NCT07577180

Conditions:Bronchopulmonary Dysplasia (BPD)|Prematurity|Very Low Birth Weight
Interventions:Vitamin A
Phase:Phase 3

Title:Pilot Trial of Supplemental Vitamin A and Nicotinamide
Status:Recruiting
updateDate:2026-03-20
Ctid:NCT05702398

Link: https://clinicaltrials.gov/ct2/show/NCT05702398

Conditions:Skin Cancer|Kidney Transplant Recipients
Interventions:Nicotinamide
Phase:Early Phase 1

View More

Title:Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
Status:Recruiting
updateDate:2025-08-12
Ctid:NCT06450925

Link: https://clinicaltrials.gov/ct2/show/NCT06450925

Conditions:Graft Vs Host Disease|Vitamin A Deficiency|Vitamin D Deficiency
Interventions:Vitamin A
Phase:Phase 2

Title:The Effect of Adjunct Vitamin a on Community-Acquired Pneumonia in Southern Iranian Children: a Randomized Clinical Trial
Status:Completed
updateDate:2024-11-07
Ctid:NCT06677684

Link: https://clinicaltrials.gov/ct2/show/NCT06677684

Conditions:Community-Acquired Pneumonia|Vitamin a
Interventions:Vitamin A
Phase:N/A

Title:Vitamin A and D Supplementation in Allogeneic HCT
Status:Recruiting
updateDate:2024-07-31
Ctid:NCT06508099

Link: https://clinicaltrials.gov/ct2/show/NCT06508099

Title:Oral Vitamin A Supplementation in Neonates With Birth Weight < 1500 g
Status:Completed
updateDate:2024-07-25
Ctid:NCT02102711

Link: https://clinicaltrials.gov/ct2/show/NCT02102711

Conditions:Bronchopulmonary Dysplasia|Retinopathy of Prematurity
Interventions:Vitamin A oral drops
Phase:N/A

Title:Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases
Status:Unknown status
updateDate:2023-03-20
Ctid:NCT05774964

Link: https://clinicaltrials.gov/ct2/show/NCT05774964

Conditions:For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method
Interventions:Folic acid
Phase:Phase 2

Title:Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A
Status:Completed
updateDate:2023-03-08
Ctid:NCT00000116

Link: https://clinicaltrials.gov/ct2/show/NCT00000116

Conditions:Retinitis Pigmentosa
Interventions:Control fatty acid
Phase:Phase 3

Title:Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection
Status:Not yet recruiting
updateDate:2023-02-09
Ctid:NCT05720559

Link: https://clinicaltrials.gov/ct2/show/NCT05720559

Conditions:Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer
Interventions:Capecitabine
Phase:Phase 2

Title:Evaluate the Safety and Tolerability, as Well as the Pharmacokinetic and Pharmacodynamic Profiles of Single and Multiple Doses of Eplontersen Administered Subcutaneously to Healthy Volunteers and Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR ).
Status:Completed
updateDate:2022-12-19
Ctid:NCT03728634

Link: https://clinicaltrials.gov/ct2/show/NCT03728634

Conditions:Healthy Volunteers|hATTR Amyloidosis
Interventions:Vitamin A
Phase:Phase 1/Phase 2

Title:Effects of Retinoids on CYP2D6 Activity During Pregnancy
Status:Completed
updateDate:2022-11-04
Ctid:NCT03117660

Link: https://clinicaltrials.gov/ct2/show/NCT03117660

Conditions:CYP2D6 Polymorphism
Interventions:Vitamin A
Phase:Phase 1

Title:Single-dose Postpartum Vitamin A Supplementation of Mothers and Neonates
Status:Completed
updateDate:2022-10-18
Ctid:NCT00198718

Link: https://clinicaltrials.gov/ct2/show/NCT00198718

Conditions:Vitamin A Deficiency|HIV
Interventions:Vitamin A (retinyl palmitate)
Phase:Phase 2

Title:High/Low Dose Vit A in Diarrhea/ALRI in Severe PEM
Status:Completed
updateDate:2022-02-11
Ctid:NCT00388921

Link: https://clinicaltrials.gov/ct2/show/NCT00388921

Conditions:Respiratory Infections|Diarrhea|Malnutrition
Interventions:Vitamin A
Phase:N/A

Title:Efficacy and Safety of Vitamin A Treatment for Children With Sepsis
Status:Unknown status
updateDate:2022-01-04
Ctid:NCT04127968

Link: https://clinicaltrials.gov/ct2/show/NCT04127968

Conditions:Vitamin A Deficiency|Pediatric|Sepsis
Interventions:Oil
Phase:N/A

Title:Comparison of the Cosmetic Effects of Bakuchiol and Retinol
Status:Completed
updateDate:2021-11-02
Ctid:NCT03112863

Link: https://clinicaltrials.gov/ct2/show/NCT03112863

Conditions:Wrinkle|Photoaging
Interventions:Retinol
Phase:Early Phase 1

Title:Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
Status:Completed
updateDate:2021-09-29
Ctid:NCT02699099

Link: https://clinicaltrials.gov/ct2/show/NCT02699099

Conditions:Malaria|Malaria Vaccines
Interventions:Stamaril
Phase:Phase 3

Title:Olfactory and Neurosensory Rehabilitation in COVID-19-related Olfactory Dysfunction
Status:Unknown status
updateDate:2021-05-25
Ctid:NCT04900415

Link: https://clinicaltrials.gov/ct2/show/NCT04900415

Conditions:Coronavirus Disease 2019
Interventions:Vitamin A
Phase:Phase 2

Title:Vitamin A and Azithromycin for Acne Vulgaris
Status:Unknown status
updateDate:2021-02-25
Ctid:NCT03090048

Link: https://clinicaltrials.gov/ct2/show/NCT03090048

Conditions:Acne Vulgaris
Interventions:Azithromycin
Phase:Early Phase 1

Title:Vitamin A for BPD Prevention
Status:Unknown status
updateDate:2020-09-24
Ctid:NCT04563429

Link: https://clinicaltrials.gov/ct2/show/NCT04563429

Conditions:The Relationship Between Oral Vitamin A Administration and the Incidence of BPD in Preterm Infants Born Before Week 29 of Pregnancy
Interventions:Oral Vitamin A
Phase:N/A

Title:Effect of Nutrition Ingredients on Microbiota Modulation
Status:Completed
updateDate:2020-03-30
Ctid:NCT03668964

Link: https://clinicaltrials.gov/ct2/show/NCT03668964

Conditions:Healthy Volunteers
Interventions:Placebo
Phase:N/A

Title:Comparison of Two Nutrition Interventions in Young Children in El Salvador
Status:Unknown status
updateDate:2019-11-13
Ctid:NCT02567981

Link: https://clinicaltrials.gov/ct2/show/NCT02567981

Conditions:Micronutrient Deficiency
Interventions:Vitamin A
Phase:N/A

Title:Intranasal Retinoic Acid Treatment for Patients With OlfactoryLOSS: A RANDOMIZED CONTROLLED TRIAL
Status:Unknown status
updateDate:2019-09-19
Ctid:NCT03574701

Link: https://clinicaltrials.gov/ct2/show/NCT03574701

Conditions:Olfactory Disorder
Interventions:Vitamin A
Phase:N/A

Title:The Correlation Between Vitamin A / E Levels and Preeclampsia
Status:Unknown status
updateDate:2019-06-03
Ctid:NCT03971604

Link: https://clinicaltrials.gov/ct2/show/NCT03971604

Conditions:Preeclampsia|Vitamin A Deficiency|Vitamin E Deficiency
Interventions:Vitamin E
Phase:N/A

Title:Retinol on Human Skin Aging in East Asian Descent
Status:Completed
updateDate:2019-04-16
Ctid:NCT02906566

Link: https://clinicaltrials.gov/ct2/show/NCT02906566

Conditions:Intrinsic Aging of Skin
Interventions:Placebo
Phase:Phase 4

Title:Effects of Early Vitamin A Supplementation on the Risk for Retinopathy of Prematurity in Extremely Preterm Infants
Status:Completed
updateDate:2018-09-05
Ctid:NCT03154723

Link: https://clinicaltrials.gov/ct2/show/NCT03154723

Conditions:Retinopathy of Prematurity
Interventions:Vitamin A
Phase:N/A

Title:Vitamin A Replacement in Patients Undergoing HSCT and Its Role on MBI-LCBI Rates
Status:Completed
updateDate:2018-05-30
Ctid:NCT03039257

Link: https://clinicaltrials.gov/ct2/show/NCT03039257

Conditions:Hematopoietic Stem Cell Transplant
Interventions:Vitamin A
Phase:N/A

Title:Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application
Status:Terminated
updateDate:2017-10-02
Ctid:NCT02758990

Link: https://clinicaltrials.gov/ct2/show/NCT02758990

Title:Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants
Status:Completed
updateDate:2017-09-26
Ctid:NCT01203488

Link: https://clinicaltrials.gov/ct2/show/NCT01203488

Title:Pilot Feasibility of Rice Bran Supplementation in Children
Status:Completed
updateDate:2017-07-21
Ctid:NCT02557373

Link: https://clinicaltrials.gov/ct2/show/NCT02557373

Conditions:Dietary Rice Bran Supplementation
Interventions:Rice Bran + Vitamin A
Phase:N/A

Title:Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa
Status:Completed
updateDate:2017-07-02
Ctid:NCT00065455

Link: https://clinicaltrials.gov/ct2/show/NCT00065455

Conditions:Retinitis Pigmentosa
Interventions:Vitamin A
Phase:Phase 1

Title:Adrenal Cortical Function and Vitamin A Deficiency in Sepsis
Status:Completed
updateDate:2017-05-16
Ctid:NCT03152474

Link: https://clinicaltrials.gov/ct2/show/NCT03152474

Conditions:Sepsis
Interventions:Vitamin A 100,000 IU
Phase:Phase 4

Title:Vitamin A Supplementation in Newborns Study
Status:Completed
updateDate:2017-03-03
Ctid:NCT00114868

Link: https://clinicaltrials.gov/ct2/show/NCT00114868

Conditions:Infant, Newborn
Interventions:Vitamin A
Phase:Phase 3

Title:Vitamin A to Reduce HIV in Vaginal Secretions and Prevent Viral Transmission
Status:Completed
updateDate:2016-12-14
Ctid:NCT00053612

Link: https://clinicaltrials.gov/ct2/show/NCT00053612

Conditions:HIV Infections|Vitamin A Deficiency|HIV Seronegativity
Interventions:Vitamin A
Phase:Phase 2

Title:Stopping Postpartum Vitamin A Supplementation: Missing Concealed Benefit
Status:Completed
updateDate:2016-09-21
Ctid:NCT02043223

Link: https://clinicaltrials.gov/ct2/show/NCT02043223

Conditions:Vitamin A Deficiency
Interventions:Placebo
Phase:Phase 2/Phase 3

Title:The Effect of Vitamin A With and Without Zinc and Multivitamin Supplementation on Malaria Morbidity in Ghanaian Children
Status:Completed
updateDate:2016-08-25
Ctid:NCT02878265

Link: https://clinicaltrials.gov/ct2/show/NCT02878265

Conditions:Malaria
Interventions:Vitamin A , Zinc and Multivitamin
Phase:Phase 3

Title:Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles
Status:Completed
updateDate:2016-04-04
Ctid:NCT01283464

Link: https://clinicaltrials.gov/ct2/show/NCT01283464

Conditions:Photodamaged Skin|Wrinkles
Interventions:Tretinoin
Phase:Phase 2

Title:Effect of Lipidic Nutrients on Memory and Well Being in Healthy Aging Adults
Status:Unknown status
updateDate:2015-12-11
Ctid:NCT02626247

Link: https://clinicaltrials.gov/ct2/show/NCT02626247

Conditions:Healthy
Interventions:Vitamin A +Long chain PUFA
Phase:N/A

Title:Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin
Status:Completed
updateDate:2015-06-24
Ctid:NCT00272610

Link: https://clinicaltrials.gov/ct2/show/NCT00272610

Conditions:Skin Aging|Purpura
Interventions:0.4% Retinol Cream
Phase:Phase 2

Title:Efficacy of Newborn Vitamin A Supplementation Versus Placebo in Improving Child Survival (NeoVitA Trial)
Status:Completed
updateDate:2015-06-01
Ctid:NCT01138449

Link: https://clinicaltrials.gov/ct2/show/NCT01138449

Conditions:Neonatal Vitamin A Supplementation
Interventions:Vitamin A
Phase:N/A

Title:Malaria in Pregnancy: Nutrition and Immunologic Effects
Status:Completed
updateDate:2015-04-24
Ctid:NCT01115478

Link: https://clinicaltrials.gov/ct2/show/NCT01115478

Conditions:Malaria|Low Birth Weight|Anemia|Perinatal Mortality
Interventions:Zinc
Phase:N/A

Title:Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis
Status:Withdrawn
updateDate:2015-04-09
Ctid:NCT00558480

Link: https://clinicaltrials.gov/ct2/show/NCT00558480

Conditions:Latent Tuberculosis Infection
Interventions:Vitamin A placebo
Phase:N/A

Title:Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients
Status:Completed
updateDate:2014-03-14
Ctid:NCT01225289

Link: https://clinicaltrials.gov/ct2/show/NCT01225289

Conditions:Relapsing Remitting Multiple Sclerosis
Interventions:Placebo
Phase:Phase 4

Title:Study of Vitamin A and Carbomer in Comforting the Ocular Surface Irritations of Glaucoma Patients
Status:Completed
updateDate:2014-03-05
Ctid:NCT02077231

Link: https://clinicaltrials.gov/ct2/show/NCT02077231

Conditions:Primary Open-angle Glaucoma
Interventions:carbomer eye gel
Phase:N/A

Title:Vitamin A Supplementation With Bacille Calmette Guerin (BCG) Vaccine
Status:Unknown status
updateDate:2013-11-15
Ctid:NCT00168610

Link: https://clinicaltrials.gov/ct2/show/NCT00168610

Conditions:Infant Mortality|Morbidity
Interventions:Vitamin A
Phase:Phase 4

Title:Vitamin A Supplementation With Routine Childhood Vaccines and Mortality and Morbidity
Status:Unknown status
updateDate:2013-11-15
Ctid:NCT00168623

Link: https://clinicaltrials.gov/ct2/show/NCT00168623

Conditions:Mortality|Morbidity
Interventions:Vitamin A
Phase:Phase 4

Title:Vitamin A and Response to Endotoxin
Status:Unknown status
updateDate:2013-11-15
Ctid:NCT00168649

Link: https://clinicaltrials.gov/ct2/show/NCT00168649

Conditions:TNF-alfa|Endotoxin Levels
Interventions:Vitamin A
Phase:N/A

Title:Vitamin A With BCG Vaccine
Status:Completed
updateDate:2013-11-15
Ctid:NCT00168597

Link: https://clinicaltrials.gov/ct2/show/NCT00168597

Conditions:Mortality|Morbidity
Interventions:Vitamin A
Phase:Phase 4

Title:Different Doses of Vitamin A Supplementation and Male and Female Morbidity and Mortality
Status:Completed
updateDate:2013-11-15
Ctid:NCT00168636

Link: https://clinicaltrials.gov/ct2/show/NCT00168636

Conditions:Mortality|Morbidity
Interventions:Vitamin A
Phase:Phase 4

Title:Effect of Vitamin A in the Treatment of Neonatal Sepsis and Necrotizing Enterocolitis
Status:Completed
updateDate:2013-09-25
Ctid:NCT00707785

Link: https://clinicaltrials.gov/ct2/show/NCT00707785

Conditions:Sepsis|Necrotizing Enterocolitis|Meningitis|Pneumonia
Interventions:Vitamin A
Phase:Phase 3

Title:Evaluation of Vitamin A and Zinc Supplementation on Malarial Morbidity
Status:Completed
updateDate:2013-02-01
Ctid:NCT01782001

Link: https://clinicaltrials.gov/ct2/show/NCT01782001

Conditions:Malaria|Malnutrition
Interventions:vitamin A and zinc
Phase:Phase 3

Title:Vitamin A and Maternal-infant Flu Vaccine Response
Status:Completed
updateDate:2013-01-03
Ctid:NCT00817661

Link: https://clinicaltrials.gov/ct2/show/NCT00817661

Conditions:Influenza
Interventions:Placebo
Phase:N/A

Title:Making Maternal Post-partum Vitamin A Supplementation Effective: The Role of Timing and Inflammation
Status:Completed
updateDate:2012-10-11
Ctid:NCT00952640

Link: https://clinicaltrials.gov/ct2/show/NCT00952640

Conditions:Healthy Women Giving Birth to Singleton Infants
Interventions:vitamin A
Phase:N/A

Title:Impact of Vitamin A on Gene Expression, in Multiple Sclerosis Patient
Status:Unknown status
updateDate:2012-07-18
Ctid:NCT01407211

Link: https://clinicaltrials.gov/ct2/show/NCT01407211

Conditions:Relapsing Remitting Multiple Sclerosis
Interventions:vitamin A
Phase:Phase 4

Title:The Study of the Effects of Vitamin A on Immune System in Patients With Atherosclerosis
Status:Unknown status
updateDate:2012-06-05
Ctid:NCT00963222

Link: https://clinicaltrials.gov/ct2/show/NCT00963222

Conditions:Atherosclerosis
Interventions:placebo
Phase:Phase 4

Title:Antioxidant Micronutrients in Malaria
Status:Completed
updateDate:2012-05-31
Ctid:NCT01152931

Link: https://clinicaltrials.gov/ct2/show/NCT01152931

Conditions:Malaria
Interventions:Artesunate + Vitamin E + Zinc
Phase:Phase 3

Title:Sub-clinical Inflammation and Iron Supplementation
Status:Completed
updateDate:2012-05-22
Ctid:NCT01198574

Link: https://clinicaltrials.gov/ct2/show/NCT01198574

Conditions:Anemia
Interventions:Placebo group
Phase:Phase 3

Title:Impact of Vitamin A on Multiple Sclerosis (MS)
Status:Unknown status
updateDate:2011-08-16
Ctid:NCT01417273

Link: https://clinicaltrials.gov/ct2/show/NCT01417273

Conditions:Relapsing Remitting Multiple Sclerosis
Interventions:Drug: placebo
Phase:Phase 4

Title:The Effect of Vitamin A on Atherosclerosis
Status:Unknown status
updateDate:2011-08-11
Ctid:NCT01414972

Link: https://clinicaltrials.gov/ct2/show/NCT01414972

Conditions:Atherosclerosis
Interventions:placebo
Phase:Phase 4

Title:Newborn Vitamin A (VA) Supplementation Pilot Project, Pakistan
Status:Completed
updateDate:2011-08-10
Ctid:NCT00674089

Link: https://clinicaltrials.gov/ct2/show/NCT00674089

Conditions:Vitamin A Deficiency
Interventions:Placebo
Phase:N/A

Title:The Effect of Vitamin A Supplementation on Cytokine Profile in Obesity
Status:Unknown status
updateDate:2011-07-29
Ctid:NCT01405352

Link: https://clinicaltrials.gov/ct2/show/NCT01405352

Conditions:Obesity
Interventions:Vitamin A
Phase:Phase 4

Title:Intratracheal Vitamin A Administration With Surfactant for Newborn Respiratory Distress Syndrome
Status:Unknown status
updateDate:2011-07-26
Ctid:NCT01265589

Link: https://clinicaltrials.gov/ct2/show/NCT01265589

Conditions:RDS|Infant, Newborn|Vitamin A|Surfactant
Interventions:surfactant+vitamin A
Phase:Phase 3

Title:Long-term Impact and Intervention for Diarrhea in Brazil
Status:Unknown status
updateDate:2011-03-08
Ctid:NCT00133406

Link: https://clinicaltrials.gov/ct2/show/NCT00133406

Conditions:Diarrheal Disorder
Interventions:zinc
Phase:Phase 3

Title:Impact of the WHO Recommended Vitamin A Supplementation at Immunisation Contacts
Status:Terminated
updateDate:2011-03-01
Ctid:NCT00514891

Link: https://clinicaltrials.gov/ct2/show/NCT00514891

Conditions:Mortality|Morbidity
Interventions:Vitamin A
Phase:Phase 4

Title:Trial of Vitamins in HIV Progression and Transmission
Status:Completed
updateDate:2010-11-11
Ctid:NCT00197743

Link: https://clinicaltrials.gov/ct2/show/NCT00197743

Conditions:HIV Infections|Disease Transmission, Vertical
Interventions:Multivitamins
Phase:Phase 3

Title:TB Nutrition, Immunology and Epidemiology
Status:Completed
updateDate:2010-08-27
Ctid:NCT00170404

Link: https://clinicaltrials.gov/ct2/show/NCT00170404

Conditions:Mycobacterium Tuberculosis
Interventions:Vitamin A
Phase:Phase 3

Title:Micronutrients and Enteric Infections in African Children
Status:Completed
updateDate:2010-08-27
Ctid:NCT00133419

Link: https://clinicaltrials.gov/ct2/show/NCT00133419

Conditions:Enteric Infections
Interventions:Vitamin A + Zinc
Phase:Phase 2

Status:Completed
gid:232235488
srcid:4
updateDate:2010-02-18
Ctid:NCT00211341
cids:445354

Link: https://clinicaltrials.gov/ct2/show/NCT00211341

Title:Trial of the Impact of Vitamin A on Maternal Mortality
Conditions:Vitamin A Deficiency|Maternal Mortality|Maternal Morbidity
Interventions:Vitamin A
Phase:Phase 3
diseaseids:11422|9604

Status:Completed
gid:232238336
srcid:4
updateDate:2009-09-17
Ctid:NCT00000114
cids:14985|445354

Link: https://clinicaltrials.gov/ct2/show/NCT00000114

Title:Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa
Conditions:Retinitis Pigmentosa
Interventions:Vitamin A
Phase:Phase 3
diseaseids:9093

Status:Completed
gid:232160685
srcid:4
updateDate:2009-07-29
Ctid:NCT00742937
cids:445354

Link: https://clinicaltrials.gov/ct2/show/NCT00742937

Title:Impact of Maternal Supplementation With Dual Megadose of Vitamin A
Conditions:Hypovitaminosis|Vitamin A Deficiency
Interventions:Placebo
Phase:Phase 2/Phase 3
diseaseids:9604

Status:Completed
gid:232219782
srcid:4
updateDate:2005-10-28
Ctid:NCT00222547
cids:2082|445354

Link: https://clinicaltrials.gov/ct2/show/NCT00222547

Title:Deworming and Enhanced Vitamin A Every 6 Month in Rural Indian Children Aged 1-6
Conditions:Village Children
Interventions:Albendazole
Phase:Phase 4
diseaseids:

Status:Completed
gid:232282274
srcid:4
updateDate:2005-09-15
Ctid:NCT00168584
cids:445354

Link: https://clinicaltrials.gov/ct2/show/NCT00168584

Title:Different Doses of Vitamin A and Childhood Morbidity and Mortality
Conditions:Mortality|Morbidity
Interventions:Vitamin A
Phase:Phase 4
diseaseids: